By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
Herpes simplex virus (HSV), varicella-zoster virus, and other viruses can cause infections that can be treated with the antiviral drug valacyclovir. (VZV). As a prodrug of acyclovir, valacyclovir is transformed into the drug by the body.
By preventing the virus from replicating, valacyclovir serves to lessen the severity and duration of the infection’s symptoms. It is frequently applied to the treatment of shingles, genital herpes, and cold sores.
Tablets of valacyclovir are available and are commonly swallowed. The type of infection being treated, along with other variables like the patient’s age and general condition, may affect the dosage and length of the course of treatment.
To guarantee that the medication is both effective and safe for you to use, it is crucial to adhere to the dosing recommendations given by your healthcare professional.
Valacyclovir functions best when taken within 48 hours of the onset of shingles or genital herpes symptoms. It is advised to start therapy for genital herpes in adults no more than 48 hours after the first signs of the illness appear.
For the best benefits, the majority of doctors advise beginning valacyclovir within 72 hours of recognising symptoms. Valacyclovir should be used within 24 hours of the onset of symptoms in people with recurrent genital herpes.
The use of valacyclovir will not treat or stop the spread of genital herpes. However, it can decrease infection symptoms.
Global Velacyclovir market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Valacyclovir was introduced by GlaxoSmithKline (GSK) under the trade name Valtrex. Since then, other generic valacyclovir products have been introduced to the market. A generic version of Valtrex was introduced by Sandoz in the US. A generic version of Valtrex was introduced by Ranbaxy Laboratories in the US that same year.
Mild cognitive impairment (MCI) may be treated with valacyclovir. Valacyclovir’s ability to treat MCI is now being examined in a Phase II clinical trial.
The experiment is examining whether valacyclovir can slow down cognitive deterioration in MCI patients who test positive for serum herpes simplex virus type 1 or 2 antibodies. The trial is anticipated to be finished.
GSK introduced valacyclovir under the trade name Valtrex. Since then, a number of generic valacyclovir products have been introduced to the market, including those from Sandoz and Ranbaxy Laboratories. Additionally, valacyclovir is being researched for its possible use in the management of moderate cognitive impairment.
